Back to library
GH SecretagogueSubcutaneous
IGF-1 LR3
Also known as: Long-R3-IGF-1 · Long R3 IGF-1
Recombinant insulin-like growth factor-1 with an Arg→Glu substitution at position 3 and a 13-amino-acid N-terminal extension. The modifications block IGFBP-3 binding, extending serum half-life and increasing receptor availability.
At a glance
- Half-life
- 20 hours
- Common route
- Subcutaneous
- Typical dose range
- 20–100mcg
- Stability (reconstituted)
- 30days refrigerated
Best timing
Once daily, often post-workout into the trained muscle group. Hypoglycemia risk peaks 30–60 minutes post-dose — pair with carbohydrates.
Contraindications
- Active cancer (IGF-1 is mitogenic across many tumor types)
- Pregnancy
- Diabetic retinopathy
- Severe hypoglycemia history
- Adrenal insufficiency
Watch symptoms
- Hypoglycemia (significant — especially fasted)
- Lightheadedness, sweating, tremor
- Localized muscle pumps or fullness
- Numbness, carpal tunnel symptoms
- Joint pain or jaw growth at sustained high doses
Citations